Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
LUND, Sweden, Nov. 11, 2016 -- Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the pivotal clinical Phase 2 ARPEGGIO study, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Preclinical results concerning laquinimod were presented at the ECTRIMS 2016 Congress held in London, UK, on September 14-17, 2016
- Special Protocol Assessment (SPA) for laquinimod rescinded after discussions with the FDA
ANYARA
- Licensing agreement entered into with NeoTX Therapeutics Ltd
Tasquinimod, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
New share issue
- The Board of Directors has today decided, based on the authorization granted by the Annual General Meeting, to implement a rights issue totaling approximately SEK 55 M
- The issue is at no cost guaranteed in full by the company's largest owner MGA Holding AB
Financial summary
| SEK M | July - Sept | Jan - Sept | Full Year | ||
| 2016 | 2015 | 2016 | 2015 | 2015 | |
| Net sales | 4.1 | 5.2 | 12.0 | 11.3 | 16.3 |
| Operating loss | -11.1 | -22.2 | -41.6 | -149.7 | -177.9 |
| Loss for the period | -12.4 | -23.4 | -44.8 | -152.7 | -193.5 |
| Loss per share, before and after dilution (SEK) | -0.14 | -0.26 | -0.50 | -1.70 | -2.15 |
| Cash and cash equivalents (at the end of the period) | 39.9 | 132.4 | 103.6 | ||
- Operating costs reduced by 67 % (SEK 107.4 M) compared with 2015
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 46 19 20 95 Hans Kolam, CFO Tel: +46 46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 05 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/2d930325-016d-4aa6-8819-12468608eb0b
